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Summary
 
Antibody responses against antibodies, such as rheumatoid factors, are found in several immu-
nopathological diseases and may play a role in disease pathogenesis. Experience shows that they
are usually difficult to induce experimentally. Antibodies specific for immunoglobulin constant
regions (anti-allotypic) or for variable regions (anti-idiotypic) have been investigated in animal
models; the latter have even been postulated to regulate antibody and T cell responses via net-
work-like interactions. Why and how such anti-antibodies are induced during autoimmune
diseases, has remained largely unclear. Because repetitively arranged epitopes in a paracrystalline
structure of a viral envelope cross-link B cell receptors efficiently to induce a prompt T-inde-
pendent IgM response, this study used immune complexes containing viruses or bacteria to
evaluate the role of antigen pattern for induction of anti-antibody responses. We present evi-
dence that antibodies bound to strictly ordered, but not to irregularly arranged, antigens dra-
matically enhance induction of anti-antibodies, already after a single immunization and without
using adjuvants. The results indicate a novel link between anti-antibody responses and infec-
tious agents, and suggest a similar role for repetitive self-antigens such as DNA or collagen in-
volved in chronic immunopathological diseases.
 
A
 
ntibodies against the constant and the variable parts of
immunoglobulins have been investigated in various
studies. Anti-allotypic antibodies directed against heterolo-
gous and rheumatoid factors (RF)
 
1
 
 directed against autolo-
gous constant immunoglobulin regions have been induced
by immunization with immune complexes (IC) that con-
tained antibodies bound to hemocyanin (1), transferrin (2),
collagen (3), or LPS (4). Anti-allotypic antibodies were
mainly observed in experimental situations after immuniza-
tion with heterologous immunoglobulin aggregates to-
gether with adjuvants (5), whereas RF (6–8) occur under
physiological conditions and were shown to have various
beneficial effects, such as clearance of IC from the blood
(9), enhanced antigen presentation (10), and neutralization
of certain pathogens as shown for herpes simplex virus in
vitro (11) and trypanosomes in vivo (12). However, RF
may be involved in the pathogenesis of synovitis in rheu-
matoid arthritis (13, 14) and of some immune complex dis-
eases (15), because they can form immune complexes and
efficiently activate the complement system (16). In con-
trast, anti-idiotypic antibodies have been postulated to play
a role in the regulation of antibody (17, 18) and T cell re-
sponses (19, 20) via network-like interactions. Experimen-
tal induction of anti-antibodies in general is difficult and re-
quires adjuvants plus allotypic or species differences (18);
therefore, conclusions from these experiments for the role
of anti-idiotypic antibodies are limited, and the biological
significance of these antibodies is still unclear.
Because there is good evidence that repetitively arranged
epitopes in a paracrystalline structure of a viral envelope
cross-link B cell receptors efficiently to induce a prompt
T-independent IgM response (21), this study attempted to
test whether immune complexes with viruses or bacteria
exhibiting highly ordered repetitive antigens on their sur-
face may play a role in the induction of anti-antibody re-
sponses.
 
1
 
Abbreviations used in this paper:
 
 HRPO, horseradish peroxidase; IC, im-
mune complex; 
 
P.a.
 
, 
 
Pseudomonas aeruginosa
 
; RF, rheumatoid factors; 
 
S.t.
 
,
 
Salmonella typhi
 
; TS, trypic soy; VSV, vesicular stomatitis virus; VSV-G,
VSV glycoprotein; VSV-G–huH
 
g
 
1, fusion protein of VSV-G with hu-
man IgG1 heavy chain constant regions; VSV-IND, VSV serotype Indi-
ana; VSV-NJ, VSV serotype New Jersey.
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Materials and Methods
 
Infectious Agents.
 
VSV serotype Indiana, (VSV-IND, Mudd
Summers isolate) and VSV serotype New Jersey, (VSV-NJ, Prin-
gle isolate) were originally obtained from Professor D. Kolakow-
sky (University of Geneva, Switzerland) and grown on BHK cells
in minimal essential medium. UV inactivation was performed as
described earlier (22) and monitored by a plaque assay on Vero
cells. Recombinant VSV-G protein was produced in a baculovi-
rus expression system as described (23); recombinant baculovirus
expressing VSV-G was a gift from Dr. D.H.L. Bishop (NERC In-
stitute of Virology, Oxford, UK). 
 
Salmonella typhi 
 
strain E.83.728
was provided by F. Sadallah (University of Geneva, Switzerland).
 
Pseudomonas aeruginosa
 
 strain Fischer IT-2 was obtained form the
Swiss Serum and Vaccine Institute. Both bacteria were grown in
tryptic soy (TS) broth at 37
 
8
 
C, quantified on TS agar plates and
inactivated as a thin layer in a petri dish by UV irradiation for 10
min (Philips UV lamp, 15 W, distance 8 cm).
 
Antibodies and IC.
 
Anti-VSV mAb were obtained by fusion
of a VSV-immune spleen from BALB/c mice on day 4 after pri-
mary (for IgM-secreting hybridomas) or on day 4 after secondary
infection (for IgG-secreting hybridomas). The antibodies WN1
222-5 and WN4 245-2 (both IgG2a) are broadly reactive anti-
LPS–core antibodies derived from NZB mice (24). The antibod-
ies 99-T2 (IgG2b) and 63-T2 (IgM) are highly specific anti-LPS–
O-chain antibodies against 
 
Pseudomonas aeruginosa 
 
strain Fisher IT-2
and were generated in BALB/c mice (25). IC were generated by
incubation of a mixture of UV-inactivated virus or bacteria with
the respective antibodies for 1 h at room temperature. IC forma-
tion in the VSV model could be demonstrated indirectly by re-
duction of anti-VSV neutralizing antibody titers in mice immu-
nized with IC compared with mice immunized with VSV alone.
 
ELISA for Anti-antibody Detection.
 
We used a sandwich ELISA
with the following steps: (
 
a
 
) coating with isotype-specific goat anti–
mouse antibody (1 
 
m
 
g/ml; Southern Biotechnologies, Birming-
ham, AL), (
 
b
 
) blocking with 2% BSA (Fluka, Buchs, Switzerland)
in PBS, (
 
c
 
) mAb supernatant (0.2 
 
m
 
g/ml), (
 
d
 
) 20-fold prediluted
mouse serum, titrated 1:2 over 11 dilution steps, (
 
e
 
) isotype-specific
horseradish peroxidase (HRPO)–labeled goat anti–mouse antibod-
ies(0.5 
 
m
 
g/ml, Southern Biotechnologies), (
 
f
 
) substrate ABTS
(2.2
 
9
 
-azino-di-[3-ethylbenzthiazolin-sulfonate (6)], Boehringer Mann-
heim) and H
 
2
 
O
 
2
 
 (Fluka). Plates were coated over night at 4
 
8
 
C, all
other incubations were for 60 to 90 min at room temperature.
Between incubations, plates were washed three times with PBS
containing 0.5 ml Tween 20 per liter. OD was measured at 405
nm in an ELISA reader. All anti-antibody titers are indicated as -log
 
2
 
of 20-fold prediluted sera. For Fig. 1, 
 
C 
 
and 
 
D
 
, the dilution step
at half maximal OD was determined as shown in Fig. 1 
 
A
 
 and then
taken as anti-antibody titer. For Fig. 1 
 
E
 
, allotype-specific anti-
IgM antibodies (Southern Biotechnologies) were used for coating
and detection at the same concentrations as described above.
 
VSV Neutralization Assay.
 
VSV-IND neutralizing antibodies
(Fig. 2) were determined on the indicated timepoints by a plaque
reduction assay on Vero cells as described before (26). Titers are
indicated as -log
 
2
 
 of 40-fold prediluted sera.
 
VSV-G–huH
 
g
 
1.
 
VSV-G–huH
 
g
 
1 fusion protein was gener-
ated following procedures developed by Traunecker and Kar-
jalainen (27) and will be described elsewhere (Bucher, E., U.
Figure 1. IgG anti-IgM response after im-
munization with immune complexes versus un-
complexed antigen. (A) BALB/c or (B) A/J
mice were immunized twice (interval, 14 d)
with 1 mg of the monoclonal anti-VSV-G IgM
antibody M1 complexed with 108 PFU UV-
inactivated VSV (closed squares), 10 mg of recom-
binant VSV-G (closed triangles), or 4 mg of rat
anti–mouse Ck antibody (closed circles), with IgM
alone (open diamonds) or with VSV alone (open
squares). 6 d after secondary immunization, IgG
anti-IgM titers were determined by ELISA as
described in Materials and Methods. (C) IgG
anti-IgM titers of 20-fold prediluted sera were
determined over a time period of 80 d after pri-
mary immunization as described in A. The same symbols are used. (D) Dose dependence of IgG anti-IgM induction shown by immunization of BALB/c
mice with IC made of 108 PFU UV-inactivated VSV and titrated amounts of two different monoclonal anti-VSV-G IgM antibodies M1 (closed bars) and
M3 (open bars). (E) C57BL/6 mice were immunized once with 5 mg of the monoclonal anti-VSV-G IgM antibody M5 complexed with 108 PFU UV-
inactivated VSV (closed squares), with 5 mg of M5 alone (open diamonds) or with 108 PFU VSV alone (open squares). 4 d later, IgMa-specific IgMb antibodies
were determined by ELISA as described in Materials and Methods. 
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Kalinke, C. Lopez, T. Fehr, H. Hengartner, and R.M. Zinkerna-
gel, manuscript in preparation). Mouse IgG anti-huIgG titers
were determined by ELISA as described in Fig. 1 on plates coated
with whole human serum diluted 1:100 in coating buffer. In vivo
CD4
 
1
 
 T cell depletion was performed as described in Table 1.
 
Results
 
Induction of Anti-antibodies by VSV–IgM Complexes.
 
A strictly
repetitive paracrystalline order of antigen in a viral enve-
lope with a spacing of 5 to 10 nm has been shown to facili-
tate B cell responses, even to self-antigen (28). To evaluate
whether antibodies bound to such highly organized antigens
might also be presented in an ordered and repetitive fashion
and therefore could induce anti-antibodies, BALB/c mice
were immunized with IC of autologous antibodies bound
to vesicular stomatitis virus (VSV) particles exhibiting para-
crystalline strictly repetitive glycoproteins (G) in their en-
velope. Control groups were immunized with irregularly
complexed or monomeric antibodies. While in vitro–gen-
erated IC containing 1 
 
m
 
g of a monoclonal IgM antibody
M1 against VSV-G and 10
 
8
 
 PFU of UV-inactivated VSV
particles efficiently induced anti-antibodies, IC with the
same amount of antibody M1 either irregularly complexed
with the recombinant VSV-G protein spontaneously ag-
gregating in tail-to-tail micelles (28a) or cross-linked with a
rat anti–mouse C
 
k
 
 antibody did not (Fig. 1 
 
A
 
). Similar re-
sults were obtained in A/J and C57BL/6 mice, but in this
situation, IgG anti-IgM antibodies could also be induced by
the poorly organized IC containing recombinant VSV-G,
although at much lower titers than with the highly repeti-
tive complex (Fig. 1 
 
B
 
). When BALB/c mice were boosted
once after 14 d, only those treated with virus/antibody com-
plexes exhibited IgM-specific IgG titers of 1:3,000, which
did not drop significantly over a period of 80 d (Fig. 1 
 
C
 
).
They were dependent on the antibody dose used for gener-
ation of IC, as shown for two different monoclonal IgM
(Fig. 1 
 
D
 
). In similar experiments using different VSV-spe-
cific monoclonal IgG instead of IgM antibodies, no anti-anti-
bodies were induced. This might be explained as follows: (
 
a
 
)
the potentially immunogenic variable domains of IgG mol-
ecules binding to the virus surface are not easily accessible
to B cells, or (
 
b
 
) clearance and processing of IgG- and IgM-
containing IC is distinct, because the former, but not the
latter, exhibit easily accessible Fc domains that could bind
to Fc receptors of macrophages, which would then lead to
faster clearance of the IC. Also VSV infection itself did not
induce anti-antibodies, probably because the virus only
abortively replicates extraneuronally in mice and is rapidly
eliminated within 1 d (29), before neutralizing IgM anti-
bodies, which could lead to IC formation, are measured.
 
Specificity of Anti-antibodies Induced by VSV–IgM Com-
plexes.
 
To determine the specificity of these anti-antibod-
ies, we immunized BALB/c mice (IgM
 
a
 
) or A/J mice (IgM
 
e
 
)
with IC formed with six different monoclonal VSV neu-
tralizing IgM (M1–M6), which were isolated from BALB/c
mice. M3 is specific for the distinct serotype VSV-New Jersey
(VSV-NJ), the others for VSV Indiana (VSV-IND). Analysis
of these sera on ELISA plates coated with M1 to M6 revealed
that BALB/c mice produced anti-antibodies exclusively spe-
cific for the IgM used for immunization, whereas sera of
A/J mice recognized any IgM as long as they were of
BALB/c origin (Table 1). A monoclonal IgM of A/J origin
as well as IgM of normal A/J serum was not recognized by
either of the sera (data not shown). Therefore, the anti-anti-
bodies induced in BALB/c mice are idiotype specific,
whereas those induced in A/J mice were allotype-specific.
One antibody (M2) failed to induce anti-antibodies (Table 1,
Experiment 1); this correlated with its 10–100-fold lower
neutralizing capacity and IC formation in vitro compared
with the other IgM (data not shown). Both BALB/c anti-
idiotypic and A/J anti-allotypic antibodies were IgGs and,
therefore, T helper cell dependent; this is demonstrated by
the failure of CD4
 
1
 
 T cell–depleted or of athymic nude
mice to respond with anti-antibodies of IgG isotype (Table 1,
Experiment 3). Anti-allotypic antibodies were also found
in C57BL/6 mice (IgM
 
b
 
), and in this case we were even
able to detect an IgM
 
a
 
 allotype-specific response on day 4
after primary immunization with IC (titers of 1:100), but not
after immunization with virus or antibody alone (Fig. 1 
 
E
 
).
This response could be prolonged by additional use of LPS
(data not shown).
Next, it was tested whether the specificity of induced
anti-antibodies as shown in ELISA could also be demon-
strated in an independent in vivo read out. For this pur-
pose, A/J and BALB/c were immunized twice with IC
containing 10
 
8
 
 PFU inactivated VSV-NJ and 5 
 
m
 
g of the
antibody M3 to induce anti-antibodies. 10 d later these
mice were treated with a specific IgM anti-VSV-IND anti-
body (M5), that did not cross-react with VSV-NJ. This en-
abled us to measure the half life of M5 by determining the
neutralizing titer of the sera against VSV-IND (Fig. 2). In
A/J mice, the half-life of M5 was reduced from 28 to 4 h,
whereas in BALB/c mice it was comparable to unimmu-
nized controls; this confirmed the presence of antibodies
against the constant region of BALB/c immunoglobulin in
A/J, but not in BALB/c mice. Thus, in this model situa-
tion anti-allotypic antibodies could be shown to modulate
serum IgM antibodies by forming IC in vivo. We were not
able to use the same experimental approach to assess modu-
Figure 2. In vivo half-life of
an IgM antibody (M5) in mice
with or without anti-antibody ti-
ters. A/J (closed symbols) or
BALB/c mice (open symbols)
were twice (interval, 14 d) in-
jected with VSV-NJ/M3 IC to
induce anti-antibodies. 10 d after
the second injection these mice
(squares) and not immunized
controls (diamonds) were in-
jected with 5 mg of anti-VSV-
IND IgM (M5), and VSV-IND
neutralizing titers were measured
at the indicated timepoints. In
vivo half-life of M5 was deter-
mined by regression analysis. 
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lation by anti-idiotypic antibodies, because the immuniza-
tion with IC itself induced specific long-lived virus-neu-
tralizing antibodies of IgG type.
 
Induction of Anti-antibodies by Bacteria–IgG Complexes.
 
To evaluate whether these findings hold true not only for
VSV, but also for bacteria exhibiting highly repetitive anti-
gens on their surface, IC formed with gram negative bacte-
ria (exhibiting regularly spaced LPS molecules) and anti-LPS
antibodies were tested. 10
 
8
 
 CFU of 
 
Salmonella typhi
 
 (
 
S.t.
 
)
(Fig. 3 
 
A
 
) or 
 
Pseudomonas aeruginosa
 
 (
 
P.a.
 
) (Fig. 3 B) were
UV-inactivated and complexed with a monoclonal IgG2a
(origin: NZB) or IgG2b (origin: BALB/c) anti-LPS antibody,
respectively, to immunize BALB/c mice. After 14 d, these
mice were boosted once, and 6 d later IgG anti-IgG anti-
bodies were found in both situations. The induction of these
anti-antibodies was again dependent on the antibody dose
used to form IC, as shown for S.t. (Fig. 3 A). With the
highest dose (108 CFU) immunization with bacteria alone
also induced some anti-antibodies, but at much lower titers
than with IC. To test whether these results reflected poly-
clonal B cell activation by the bacterial LPS, we immu-
nized LPS-responder (C3H/HeN, BALB/c) and LPS-non-
responder (C3H/HeJ) mice with IC or noncomplexed
antibodies (Fig. 3 D) and tested the BALB/c sera on differ-
ent antibodies of the same isotype (Fig 3 C). The results in-
dicate: (a) Efficient LPS-mediated stimulation of B cells in
the case of P.a., which, however, depended on the pres-
ence of IC; the induced anti-antibodies were of rheuma-
toid factor type because they recognized any autologous
IgG2b of BALB/c origin (Fig. 3 C). (b) Successful induc-
tion of specific anti-allotypic antibodies by IC with S.t.,
which recognized only heterologous NZB-derived IgGs
Table 1. Specificity and Helper T Cell Dependence of Anti-antibodies in BALB/c and A/J Mice
Experiment* Mouse strain Immunization
Anti-antibody titer‡ on plates coated with
M1§ M2 M3 IgM anti-P.a.
1 BALB/c IND/M1 (G7G9C9) 7 ,1 ,1 ,1
IND/M2 (M4C11H12) ,1 ,1 ,1 ,1
NJ/M3 (B3B8H6) ,1 ,19 , 1
A/J IND/M1 7.5 7 8 6
IND/M2 ,1 ,1 ,1 ,1
NJ/M3 6 6 7.5 4
M4 M5 M6 IgM anti-P.a.
2 BALB/c IND/M4 (M3F2B6) 5 ,1 ,1 ,1
IND/M5 (H2F1C1) ,17 , 1, 1
IND/M6 (M4E11G8) ,1 1 7.5 ,1
A/J IND/M4 6.5 4 2 2
IND/M5 8 9.5 5.5 6.5
IND/M6 3 3 6 2
CD41 T cells M3 M5
3 BALB/c IND/M5 Normal ,18
IND/M5 Depletedi ,1 ,1
BALB nu/nu IND/M5 Absent ,1 ,1
A/J NJ/M3 Normal 7.5 5
NJ/M3 Depletedi 2 ,1
*BALB/c (IgMa) and A/J (IgMe) mice were immunized twice with 108 PFU of inactivated VSV complexed with 3 to 8 mg of various anti-VSV-G
IgM antibodies (M1–M6) with an interval of 14 d.
‡IgG anti-IgM titers are indicated as 2log2 of 20-fold prediluted sera on day 6 after booster injection and are determined as described in Fig. 1 A.
§ELISA plates were coated with a goat anti–mouse IgM as a catcher antibody for the different IgM hybridoma supernatants M1–M6 (anti-VSV) and
63-T2 (anti–Pseudomonas aeruginosa [P.a.]).
iCD41 T cells were depleted in vivo by intraperitoneal injection of 1 mg of the anti-CD4 antibody YTS 191.6 on days 23 and 21 before immuni-
zation.1789 Fehr et al.
(Fig. 3 C) and were independent of B cell activation by
LPS (Fig. 3 D). In the case of P.a., 38% (18 of 48) of the
mice immunized twice with identical complexes died upon
the second immunization from a shock-like syndrome
compared with only 4% (2 of 48) of the control groups that
were immunized with bacteria, purified LPS, or antibody
only; this in vivo finding confirmed the presence of anti-
antibodies measured in vitro and, in addition, suggested a
pathogenic function of RF-like anti-antibodies.
Immunogenicity of Multivaltent Versus Bivalent IC. The no-
tion that antibodies bound to repetitively ordered viral or
bacterial antigens induced anti-antibodies was further tested
with a sort of inversed IC. Complexes were formed be-
tween a VSV-G–specific decavalent IgM (M1) or a bivalent
IgG2a antibody (VI49; reference 30) as core of the com-
plex that binds a fusion protein of VSV-G plus constant
part of the human IgG1 H chain (huHg1) molecule. These
IC display the Fc portions of huIgG1 as repetitive domains
and form under optimal conditions decameric (with IgM) or
dimeric (with IgG) complexes. In primary and secondary
immune responses of BALB/c mice, the fusion protein
complexed with the decavalent IgM induced much higher
titers of anti-antibodies to huHg1 than bivalent IgG-com-
plexed or the noncomplexed fusion protein alone (Fig. 4).
These anti-antibodies were of IgG isotype and T-help de-
pendent, as shown by the negative effect of in vivo CD41 T
cell depletion. Although a very rigid IC structure cannot be
assumed in this model, the results show that antibody re-
sponses to a foreign constant IgG region, which involves
species differences, can be markedly enhanced by multimeric
aggregation compared with dimers or monomers. Impor-
tantly, they may even suggest that IgM-bound antigen in
turn binding IgG may be able to induce anti-IgG antibodies.
In conclusion, the presented data suggest that anti-anti-
bodies may be induced by antibodies bound to highly or-
dered repetitive antigens, but not by antibodies bound to
oligo- or monomeric antigens. Formation of IC was neces-
sary for induction of anti-allotypic, anti-idiotypic and RF-
Figure 3. IgG anti-IgG titers after immunization with antibodies complexed to Salmonella typhi (S.t.) and Pseudomonas aeruginosa (P.a.). (A) BALB/c
mice were immunized twice (interval 14 d) with 108 CFU of S.t. complexed with 20 mg (closed squares) or 2 mg (closed triangles) of the anti-LPS antibody
WN1 222-5 (IgG2a) or with 108 (open squares) or 106 (open triangles) CFU of S.t. alone or with 20 mg of antibody WN1 222-5 alone (open diamonds). 6 d
after the second injection, IgG2b plus IgG1 anti-IgG2a titers in 20-fold prediluted sera were determined in a sandwich ELISA. (B) BALB/c mice were
immunized twice with 108 PFU of P.a. complexed with 7 mg of the anti-LPS antibody 99-T2 (IgG2b) (closed squares), with 108 CFU of P.a. alone (open
triangles) or with 7 mg of 99-T2 alone (open diamonds). IgG2a plus IgG1 anti-IgG2b titers of 20-fold prediluted sera were determined in a sandwich
ELISA. (C) Sera of BALB/c mice immunized twice with IC or with bacteria alone as described in A or B were tested on ELISA plates coated with dif-
ferent antibodies of the corresponding isotype, and anti-antibody titers were determined as described in Fig 1. (D) BALB/c, LPS-responsive C3H/HeN,
and LPS-nonresponsive C3H/HeJ mice were immunized twice with IC, and anti-antibody titers were determined 6 d after booster injection as described
in the legend to Fig 1. Bars in C and D represent geometrical means of 2–3 animals per group. Standard deviation was within 6 one dilution step. Re-
sults of one out of three comparable experiments are shown.1790 Induction of Anti-antibodies by Repetitive Immune Complexes
like antibodies. However, when allotypic (Fig. 1 B) or spe-
cies differences (Fig. 4) were the target, anti-antibodies
could be induced by poorly organized aggregates, whereas
anti-idiotypic antibodies were only induced with highly or-
dered IC (Fig. 1 A). Induction of RF could only be dem-
onstrated in the Pseudomonas model (Fig. 3 B), where in
addition to repetitive antigen order the B cell stimulator
LPS was necessary (LPS alone or IC containing purified LPS
were not sufficient). These findings confirm that autoreac-
tive B cells including those with specificity for membrane-
bound self-antigens (e.g., immunoglobulin) may not be de-
leted (28, 31) and perhaps exert biological effects. It will be
interesting to evaluate the relevant differences to various
other membrane-bound self-antigens that cause deletion of
autoreactive B cells (32–34).
Our findings indicate a novel link between anti-antibody
responses and infectious agents or repetitive self-antigens.
The role of highly ordered multimeric antigen patterns for
efficient B cell activation has been tested systematically in
several model situations involving linear (flagellin [35];
haptenated polymers [36]) or particulate antigens (Hepatitis
B core antigen [37] or VSV [26]). Most infectious agents in-
cluding viruses, bacteria, and parasites expose highly or-
dered repetitive antigenic epitopes on their surface. They
are able to induce efficient T-independent IgM responses
by cross-linking B cell receptors (21, 26, 38, 39). This
study now demonstrates that the same rules seem to apply
for induction of anti-antibodies. These anti-antibodies were
readily induced after only two injections of repetitive IC
involving mAbs, but without using adjuvants. In view of
the observation that protective anti-Haemophilus influenzae
(40) and anti-viral antibodies (30) are of restricted or virtu-
ally monoclonal specificity, our results with mAbs against
infectious agents can probably be generalized. These find-
ings may explain the secretion of RF during virus infections
(influenza [41]), rubella, CMV, EBV, HIV) (6) and how the
same configuration together with or without LPS may sus-
tain anti-antibody responses in the course of bacterial infec-
tions (such as bacterial endocarditis, tuberculosis, or syphi-
lis; for review see 42). Especially chronic infections with
persistence of the pathogen during an ongoing antibody re-
sponse would fulfill the conditions for IC formation in
vivo, as it is described for herpesviruses (43, 44), HIV (45,
46), or mycobacteria (47, 48). In addition, the results in
BALB/c mice could suggest that, instead of RF, anti-idio-
typic antibodies may enhance immunopathology found in
reactive forms of arthritis, which are apparently RF nega-
tive. Also, repetitive self antigens (e.g., collagen II [49] in
rheumatoid lesions, DNA [50] in SLE) exposed after pri-
mary or secondary tissue injury may induce anti-antibodies
by formation of highly repetitive immune complexes. This
may explain why RF secretion is such a typical manifesta-
tion accompanying these diseases (15).
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Figure 4. Anti-antibody response upon immunization with a recombi-
nant VSV-G–huHg1 fusion protein alone or complexed with anti-VSV-G
IgM or IgG antibodies. BALB/c mice were immunized with 10 mg of the
fusion protein VSV-G-huHg1 alone (vertically striped bars), the fusion pro-
tein complexed with 1 mg of M1 (closed bars) or 1 mg of a monoclonal
VSV-G–specific IgG2a antibody (E5A7C9; open bars) or with 1 mg of M1
alone (horizontally striped bars). Mouse IgG (mIgG) anti-human IgG titers
of 20-fold prediluted sera were determined on day 12 after primary and
on day 5 after secondary immunization (day 18). Bars represent geometri-
cal means of two to three mice per group. Standard deviation was within 6
one dilution step.
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